HCM
HRTX icon

Highbridge Capital Management’s Heron Therapeutics HRTX Stock Holding History

Highbridge Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,697
Closed -$206K – 1535
2016
Q4 		$206K Buy
15,697
+252
+2% +$3.95K ﹤0.01% 1121
2016
Q3 		$266K Buy
+15,445
New +$287K ﹤0.01% 1062
2016
Q2 		– Sell
-19,952
Closed -$379K – 1536
2016
Q1 		$379K Buy
+19,952
New +$394K 0.01% 1088
2015
Q4 		– Sell
-159,571
Closed -$4.27M – 1614
2015
Q3 		$3.89M Buy
+159,571
New +$5.32M 0.06% 360

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Highbridge Capital Management's HRTX Position: Q1 2017 in Review

Highbridge Capital Management sold out of Heron Therapeutics (HRTX) in Q1 2017, closing a stake of 15,697 shares — an estimated $206K sold.

Highbridge Capital Management first reported a position in HRTX in Q3 2015 and held it in 4 quarters. The position peaked at $3.89M in Q3 2015. 100 funds tracked by Wall St. Rank hold HRTX as of Q1 2017.

  • Highbridge Capital Management reported no remaining Heron Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 15,697 Heron Therapeutics shares in Q1 2017, an estimated $206K.
  • Highbridge Capital Management first reported a position in Heron Therapeutics in Q3 2015 and held it in 4 quarters.
  • Highbridge Capital Management's Heron Therapeutics position peaked at $3.89M in Q3 2015.
  • 100 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2017.

Based on Highbridge Capital Management's 13F filing for Q1 2017, filed 15 May 2017.